# Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

> **NCT07229339** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 16 (estimated)

## Conditions studied

- Lung Non-Squamous Non-Small Cell Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Pemetrexed
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Zipalertinib

## Key facts

- **NCT ID:** NCT07229339
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-06-01
- **Primary completion:** 2029-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229339, "Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07229339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*